Emre Yekedüz/X
Feb 8, 2025, 15:19
Emre Yekedüz: Long-term follow-up of TIVO-3 highlights key findings in CPI-treated mRCC
Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared an article by Miguel Zugman, et al. on X:
“Long-term follow-up of TIVO-3 highlights key findings in CPI-treated mRCC:
- PFS benefit: Tivozanib 7.3 vs. Sorafenib 5.1 months (HR 0.55)
- OS trend: HR 0.69, favoring tivozanib (18.1 vs. 20.9 months)
- Durable response: Tivozanib DOR 20.3 vs. Sorafenib 5.7 months
- Safety: Lower VEGF-TKI-related grade ≥3 AEs vs. sorafenib”
Authors: Miguel Zugman, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 9, 2025, 15:42
Feb 9, 2025, 15:39
Feb 9, 2025, 15:39
Feb 9, 2025, 15:35
Feb 9, 2025, 15:16
Feb 9, 2025, 15:15
Feb 9, 2025, 15:13
Feb 9, 2025, 15:09